ANGELINI VENTURES AND EIB CO-LEAD $58 MILLION SERIES A FINANCING IN ROUGE THERAPEUTICS TO ADVANCE FIRST-IN-CLASS TREATMENT FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA

Reuters · 3d ago

Please log in to view news